ClinicalTrials.gg

Program

Cross-over to JYP0322

A development code.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Guangzhou JOYO Pharma.

Furthest: phase 3, since Aug 19, 20251 company-led study, 1 open or runningNext primary completion: Oct 31, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Guangzhou JOYO Pharma11 open or runningphase 3since Aug 19, 2025Aug 19, 2025Oct 31, 2027phase 3 · NCT07154368

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 19, 2025First study: phase 3 study in Carcinoma, Non-Small-Cell LungFirst studyNCT07154368 · 207 planned

Ahead

  1. Oct 31, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT07154368

TargetBeta

ROS1 →read by rule
“JYP0322 is an orally available inhibitor of ROS1 (coded by the gene ROS1).”study text, by rule · the study

Other programs on ROS1

ProgramCompanyFurthest phaseStudies
CrizotinibrulePfizerphase 431
taletrectinibruleNuvation Biophase 311
repotrectinibruleBristol-Myers Squibbphase 39
FudotinibruleGuangzhou JOYO Pharmaphase 33
Radiosensitizer VS-101rulevspharmtech-co-ltdphase 22
ROS1/NTRK Inhibitor ANS03ruleavistone-biotechnology-co-ltdphase 11
SIM0518ruleSimcere Pharmaceutical Groupphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07154368Carcinoma, Non-Small-Cell Lung3Not yet recruitingOct 31, 2027207

How it is read

Names in the registry

  • “Cross-over to JYP0322”, 1 entry

Codes read as this program: JYP0322.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.